Pharmaceutical Distribution in Europe: The Emergence of Direct-to-Pharmacy Supply

Author: Dr Faiz Kermani
Publication date: February 2008
Number of pages: 102

Pricing:

• Electronic copy (single user): £995 
• Printed copy (single user): £1,050

Download full report details (including table of contents)


Download order form

Report Summary

Pharmaceutical Distribution in Europe - The Emergence of Direct-to-Pharmacy Supply, is a market report that comprehensively reviews the business of medicines distribution in Europe. The report provides an objective perspective on important industry questions, such as:

• Will direct-to-pharmacy become the dominant method of drug distribution.
• Do pharmacists have a future beyond the administration of dispensing?
• Are counterfeit medicines now a major issues that the industry has to deal with?
• What is the current thinking on the role of parallel trade in the European market?

Key features of the report include:

- Contains 20 Case studies including these companies, Bayer, DocMorris, Galencia, IBS, Novartis, Phoenix and Pfizer.
- Unbiased synopsis of the UK's Office of Fair Trading's (OFT) report into the medicines' supply chain.
- Overview of the European pharmaceutical supply chain and the stakeholders involved in medicines distribution.
- Insight into the aggressive Pan-European expansion strategies of some wholesalers.
- Summary of regulations governing pharmaceutical wholesaling and pharmacy.

With 14 Tables and 26 Figures this report is essential reading for anyone working in the pharmaceuticals supply chain including manufacturers, wholesalers, distributors and pharmacists.

Use this report to:

- Identify key areas that will change in the pharmaceutical market structure over the next five years.
- Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.
- Understand how the regulatory environment could change to reflect new business models.